

**INTERIM REPORT  
for I-IX 2022  
Medika Group**

October 2022

---

**Management interim report****Comment on the business results for the third quarter of 2022**

Medika Group („Group“) has realised total revenue in the first nine months of 2022 in amount of HRK 3,479.0 million which is by 14.58% higher comparing to the same period of previous year. The increase in total revenues is a result of market growth.

Sales revenues which amount to HRK 3,436.9 million for the first nine months of 2022 are by 14.18% higher comparing to the same period of previous year.

Share of sales revenues in the total revenue is 98.79% while in the same period of previous year it was 99.14%.

Other operating revenues which amount to HRK 25.5 million are higher by 41.84% comparing to the same period of previous year. Share of other operating revenues in total revenue was 0.59% in the first nine months of 2021, and in the first nine months of 2022 is 0.73%.

Out of the total sales revenues, 99.74% revenues are generated on domestic market, while 0.26% is generated on the foreign market. In the first nine months of 2021, 99.76% revenues were generated on domestic market, while 0.24% were generated on the foreign market.

Material expenses amount to HRK 3,218.2 million and are 14.31% higher comparing to the same period of previous year, which is in accordance with the increase of sales revenue. The share of material expenses in the operating expenses is almost at the level of the same period of previous year and amounts to 95.66%.

Employee expenses are higher by 1.31% comparing to the same period of previous year. This increase was affected by the average number of employees, which is higher in the first nine months of 2022 compared to the same period of the previous year. Their share in the total expenses amounts to 2.74%.

Finance income has increased compared to the same period of the previous year for HRK 8.0 million, which is more than two times higher. Finance income relates entirely to interest income. This increase was exclusively influenced by the increase in income from default interest (due to the collection on hospital lawsuits).

Finance expenses have decreased compared to the same period of previous year by HRK 1.7 million, which is 43.22%. Their share in total expenditures is 0.06%.

Gross margin in the first nine months of 2021 amounted to 7.43%, while in the first nine months of 2022 amounts to 7.34%.

Gross profit (profit before taxation) amounts to HRK 112.8 million, while in the same period of previous year amounted to HRK 83.6 million, which is increase of HRK 29.2 million, or 34.99%. Higher gross profit is result of lower growth of total expenses (increase of 14.00% comparing to the same period of previous

year mostly due to the increase in operating expenses) in relation to the increase of total income (increase of 14.58% comparing to the same period of previous year due to the increase in operating income).

Operative earnings amount to HRK 98.3 million and are by HRK 19.2 million, which is 24.28% higher comparing to the same period of previous year. Higher operative earnings are result of lower growth of operating expenses (increase of 14.08% comparing to the same period of previous year) in relation to the increase of operating income (increase of 14.34% comparing to the same period of previous year).

Realised net profit amounts to HRK 92.3 million.

Transactions with the related parties in the first nine months of 2022 generated total net revenues in amount of HRK 52.0 million, which is 8.27% higher of generated revenue in the same period of previous year when it amounted to HRK 48.1 million.

Trade goods purchased from the related parties amount to HRK 215.3 million, while in the same period of previous year amounted to HRK 119.7 million, which is increase of HRK 95.6 million, or 79.94%.

Total assets amount to HRK 2 billion 967.9 million which is by 27.43% higher comparing to the beginning of the year.

Long term assets did not significantly change compared to the beginning of the year. Non-current intangible assets amount to HRK 290.9 million which is an increase by 3.15% compared to the beginning of the year, most significantly affected by the purchase of new trucks through financial leasing in January 2022, development of an application solution for the web store and an increase in the value of goodwill due to the purchase of a new pharmacy. Non-current tangible assets amount to HRK 232.3 million and did not significantly change compared to the beginning of the year.

Long-term financial assets mostly relate to investments in the associated company ZU Ljekarna Jagatić and long-term given cash loans. Long-term financial assets amount to HRK 28.2 million and decreased by 6.47% compared to the beginning of the year, due to loan repayment.

Non-current receivables refer to the given commodity loans to customers (commodity loans are due receivables that are reprogrammed and the payment has been agreed in the future periods). Non-current receivables increased by 93.50% compared to the beginning of the year, due to issued new commodity loans.

Deferred tax assets increased by 3.97% compared to the beginning of the year.

Short-term assets amount to HRK 2 billion 412.2 million which is 35.41% higher compared to the beginning of the year. In the structure of current assets, trade receivables, inventories and cash have increased, while financial assets have decreased compared to the beginning of the year.

Inventory amounts to HRK 438.0 million and has increased by HRK 81.5 million comparing to the beginning of the year, or 22.86%, due to higher procurement affected by increase in sales.

Total short-term receivables amount to HRK 1 billion 635.8 million and are higher by HRK 301.4 million, or 22.58%, comparing to the beginning of the year. Trade receivables, receivables from related parties and receivables from participating parties amount to HRK 1 billion 621.9 million and have increased by 22.13% comparing to the beginning of the year due to slower collection and sales growth.

Cash in bank and on hand amounts to HRK 334.4 million and record an increase by HRK 249.3 million comparing to the beginning of the year.

Long-term liabilities amount to HRK 101.1 million, out of which HRK 32.5 million relates to liabilities under operating leases (in accordance with IFRS 16 Leases), HRK 21.5 million relates to liabilities for received long-term loan, HRK 22.6 million to agreed instalments with suppliers, HRK 19.3 million relates to deferred tax liability, HRK 5.0 million relates to finance lease liabilities and HRK 244 thousand to received long-term deposits. Long-term liabilities decreased by HRK 18.7 million compared to the beginning of the year.

Short-term liabilities amount to HRK 2 billion 162.0 million out of which the biggest part in amount of HRK 1 billion 696.5 million relates to trade payables and HRK 411.9 million to credit indebtedness (HRK 408.2 million relates to short-term loans and HRK 3.7 million to finance lease).

Trade payables are higher by HRK 214.0 million comparing to the beginning of the year, or by 14.44%.

Total credit indebtedness of the Group amount to HRK 429.7 million which is an increase of HRK 378.1 million comparing to the beginning of the year, for the liquidity purposes. Of the total indebtedness, on 30 September 2022, HRK 21.5 million relates to long-term loan. All loans are in HRK, and there is no currency risk exposure on these items.

### **Key events**

The pharmaceutical market in the first nine months of 2022 has increased by 11.84% comparing to the same period of previous year. At the same time, sales of Medika have increased by 14.18% compared to the same period of the previous year, which resulted in an increase in the market share by 0.68 percentage points, which is 33.05%.

Credit indebtedness has increased by HRK 378.1 million compared to the beginning of the year, for the liquidity purposes.

### **Expected future development of the Group**

The Group will continue with its core business, distribution of medicinal products and medical devices and strongly develop operations with products that make the core business of the company.

The development strategy of ZU Prima Pharma is to expand the network of pharmacies throughout the territory of Croatia.

### **Treasury shares**

As at 30.09.2022. Medika holds 1,240 treasury shares.

### **Subsidiaries and associates**

The Company Medika d.d. has 100% ownership in subsidiaries Zdravstvena ustanova Ljekarne Prima Pharme and Primus nekretnine d.o.o.

ZU Ljekarne Prima Pharme has an associate ZU Ljekarne Jagatić in which it holds 49% of ownership.

On February 1, 2022, ZU Ljekarne Ljubica Pleško was purchased and merged to ZU Ljekarna Prima Pharme.

On September 1, 2022, ZU Ljekarne Delonga was merged to ZU Ljekarna Prima Pharme.

### **Related parties**

The company with major voting rights, Auctor d.o.o. owns 48.04% of the Company and has 50.10% of shares with voting rights.

Pliva Hrvatska d.o.o., Zagreb owns 25.32% of the Company and has 26.41% of the voting rights. Given the share in the ownership and business transactions with the Company, Pliva Hrvatska has significant influence on the current operations of the Company.

### **Financial risks and exposure to price risk, credit risk, liquidity and cash flow risk**

Within financial risks, foreign exchange risk is significant. The Group realizes majority of its revenue on domestic market in Croatian kuna. Purchase of goods is partly realised on the foreign market. Therefore, exposure to foreign exchange risk in changes of foreign exchange rates mainly linked to EUR arises. All borrowings are in Croatian kuna so there is no exposure to foreign exchange risk from this part.

The Group has part of assets which are interest-bearing so the Group's income and operating cash flows are dependent on changes in market interest rates.

The Group's interest rate risk arises from received and given short-term and long-term loans and borrowings with variable interest rates. Borrowings with variable interest rates expose the Group to interest rate risk from cash flows. Borrowings with fixed interest rates expose the Group to the fair value interest rate risk exposure.

The Group does not use derivative instruments to actively hedge cash flow and fair value interest rate risk exposure. However, the Group continuously monitors changes in interest rates. Various scenarios are simulated taking into account refinancing, renewal of existing positions and alternative financing.

Price risk arises from a continuous decrease in the price of HZZO's List of medicinal products and administrative approach in determining prices and margins of medicinal products. To lower this risk, the Group focused on increase of variety of products which are not limited by law in respect of the price of the product.

Majority of the credit risk relates to trade receivables. Credit risk is higher when dealing with private owned pharmacies. On the other hand, hospitals have longer collection period, but there is no risk of unpayment.

The most significant risk within market risks is a long collection period of receivables, especially HZZO and HZZO related receivables. Therefore, a significant amount of working capital is not available which significantly influences on cash flows and timely settlement of Group's liabilities.

As these receivables are directly or indirectly related to the receivables from the State institutions, the collection of these receivables should not be classified as a risk of unpayment. This indirectly increases the need for additional financing, which increases finance expenses.

The epidemic caused by the Covid-19 virus, which appeared in Croatia in March 2020, had no significant impact on the operations of the Group, both in 2020 and 2021 and in the first nine months of 2022, and the Group did not use support provided by the Republic of Croatia to companies whose business was therefore compromised.

Regarding EU restriction measures, which refers to the consequences of exposure and the impact of the Russian invasion of Ukraine, Group declares that it does not have a direct business relationship with entities from Russia or Ukraine, nor is it otherwise directly exposed to those entities in its business.

Nevertheless, the Group's management estimates that an indirect impact on the Group's operations is possible due to the impact on the entire economy on global level, mainly due to the increase in the price of energy products, both raw materials, interest rates and inflation that have increased further with the Russian invasion of Ukraine. Given the uncertain extent of the impact on the economy, the Group monitors developments and assesses the impact on business, financial situation and cash flows.

Jasminko Herceg, dipl.oec.  
President of the Management Board



**Medika**  
ZAGREB



OB  
π.

## Annex 1

## ISSUER'S GENERAL DATA

Reporting period:

1.1.2022

to

30.9.2022

Year:

2022

Quarter:

3.

## Quarterly financial statements

Registration number (MB):

03209741

Issuer's home Member

State code:

HR

Entity's registration  
number (MBS):

080027531

Personal identification  
number (OIB):

94818858923

LEI:

74780000O0R8ZVGJJO27

Institution  
code:

1339

Name of the issuer: **MEDIKA d.d.**Postcode and town: **10000****ZAGREB**Street and house number: **CAPRAŠKA 1**E-mail address: **medika.uprava@medika.hr**Web address: **www.medika.hr**Number of employees  
(end of the reporting

942

Consolidated report:

KD

(KN-not consolidated/KD-consolidated)

Audited:

RN

(RN-not audited/RD-audited)

Names of subsidiaries (according to IFRS):

Registered office:

MB:

**ZU Ljekarne Prima Pharme****Zagreb****0694975****Primus nekretnine d.o.o.****Zagreb****4439856**

Bookkeeping firm:

(Yes/No)

(name of the bookkeeping firm)

Contact person: **INES BOSNAR ŠMITUC**

(only name and surname of the contact person)

Telephone: **01/2412 551**E-mail address: **medika.uprava@medika.hr**

Audit firm:

(name of the audit firm)

Certified auditor:

(name and surname)

**BALANCE SHEET**  
balance as at 30.09.2022

in HRK

Submitter: Group Medika			
Item	ADP code	Last day of the preceding business year	At the reporting date of the current period
1	2	3	4
<b>A) RECEIVABLES FOR SUBSCRIBED CAPITAL UNPAID</b>	<b>001</b>	0	0
<b>B) FIXED ASSETS (ADP 003+010+020+031+036)</b>	<b>002</b>	<b>546.802.565</b>	<b>554.495.141</b>
<b>I INTANGIBLE ASSETS (ADP 004 to 009)</b>	<b>003</b>	<b>281.988.331</b>	<b>290.874.845</b>
1 Research and development	004	0	0
2 Concessions, patents, licences, trademarks, software and other rights	005	196.758.918	195.453.442
3 Goodwill	006	80.354.610	90.538.322
4 Advances for the purchase of intangible assets	007	2.012.013	312.013
5 Intangible assets in preparation	008	2.862.790	4.571.068
6 Other intangible assets	009	0	0
<b>II TANGIBLE ASSETS (ADP 011 to 019)</b>	<b>010</b>	<b>232.588.530</b>	<b>232.294.039</b>
1 Land	011	30.400.331	30.400.331
2 Buildings	012	126.538.137	122.257.911
3 Plant and equipment	013	21.430.008	20.875.278
4 Tools, working inventory and transportation assets	014	6.273.647	6.780.463
5 Biological assets	015	0	0
6 Advances for the purchase of tangible assets	016	1.655.022	2.286.947
7 Tangible assets in preparation	017	45.435.065	48.843.164
8 Other tangible assets	018	856.320	849.945
9 Investment property	019	0	0
<b>III FIXED FINANCIAL ASSETS (ADP 021 to 030)</b>	<b>020</b>	<b>30.145.269</b>	<b>28.194.912</b>
1 Investments in holdings (shares) of undertakings within the group	021	0	0
2 Investments in other securities of undertakings within the group	022	0	0
3 Loans, deposits, etc. to undertakings within the group	023	0	0
4. Investments in holdings (shares) of companies linked by virtue of participating interests	024	25.856.122	25.922.362
5 Investment in other securities of companies linked by virtue of participating interests	025	0	0
6 Loans, deposits etc. to companies linked by virtue of participating interests	026	0	0
7 Investments in securities	027	0	0
8 Loans, deposits, etc. given	028	4.289.147	2.272.550
9 Other investments accounted for using the equity method	029	0	0
10 Other fixed financial assets	030	0	0
<b>IV RECEIVABLES (ADP 032 to 035)</b>	<b>031</b>	<b>1.081.601</b>	<b>2.092.898</b>
1 Receivables from undertakings within the group	032	0	0
2 Receivables from companies linked by virtue of participating interests	033	0	0
3 Customer receivables	034	1.081.601	2.092.898
4 Other receivables	035	0	0
<b>V DEFERRED TAX ASSETS</b>	<b>036</b>	<b>998.834</b>	<b>1.038.447</b>
<b>C) CURRENT ASSETS (ADP 038+046+053+063)</b>	<b>037</b>	<b>1.781.424.947</b>	<b>2.412.166.698</b>
<b>I INVENTORIES (ADP 039 to 045)</b>	<b>038</b>	<b>356.486.603</b>	<b>437.992.789</b>
1 Raw materials and consumables	039	457.807	642.629
2 Work in progress	040	0	0
3 Finished goods	041	0	0
4 Merchandise	042	352.427.441	434.855.890
5 Advances for inventories	043	3.601.355	2.494.270
6 Fixed assets held for sale	044	0	0
7 Biological assets	045	0	0
<b>II RECEIVABLES (ADP 047 to 052)</b>	<b>046</b>	<b>1.334.455.094</b>	<b>1.635.816.839</b>
1 Receivables from undertakings within the group	047	6.022	2.253
2 Receivables from companies linked by virtue of participating interests	048	25.521.946	25.012.082
3 Customer receivables	049	1.302.538.135	1.596.916.421

AB 9.



4 Receivables from employees and members of the undertaking	050	34.857	44.078
5 Receivables from government and other institutions	051	4.830.159	4.470.739
6 Other receivables	052	1.523.975	9.371.266
<b>III CURRENT FINANCIAL ASSETS (ADP 054 to 062)</b>	<b>053</b>	<b>5.375.603</b>	<b>3.915.748</b>
1 Investments in holdings (shares) of undertakings within the group	054	0	0
2 Investments in other securities of undertakings within the group	055	0	0
3 Loans, deposits, etc. to undertakings within the group	056	0	0
4 Investments in holdings (shares) of companies linked by virtue of participating interests	057	0	0
5 Investment in other securities of companies linked by virtue of participating interests	058	0	0
6 Loans, deposits etc. to companies linked by virtue of participating interests	059	0	0
7 Investments in securities	060	0	0
8 Loans, deposits, etc. given	061	5.375.603	3.915.748
9 Other financial assets	062	0	0
<b>IV CASH AT BANK AND IN HAND</b>	<b>063</b>	<b>85.107.647</b>	<b>334.441.322</b>
<b>D ) PREPAID EXPENSES AND ACCRUED INCOME</b>	<b>064</b>	<b>848.678</b>	<b>1.249.865</b>
<b>E) TOTAL ASSETS (ADP 001+002+037+064)</b>	<b>065</b>	<b>2.329.076.190</b>	<b>2.967.911.704</b>
<b>OFF-BALANCE SHEET ITEMS</b>	<b>066</b>	<b>156.539.827</b>	<b>140.745.191</b>
<b>LIABILITIES</b>			
<b>A) CAPITAL AND RESERVES (ADP 068 to</b>	<b>067</b>	<b>638.928.033</b>	<b>693.311.974</b>
<b>I INITIAL (SUBSCRIBED) CAPITAL</b>	<b>068</b>	<b>209.244.420</b>	<b>209.244.420</b>
<b>II CAPITAL RESERVES</b>	<b>069</b>	<b>-2.131.085</b>	<b>-2.131.085</b>
<b>III RESERVES FROM PROFIT (ADP 071+072-073+074+075)</b>	<b>070</b>	<b>83.389.543</b>	<b>83.389.543</b>
1 Legal reserves	071	18.548.510	18.548.510
2 Reserves for treasury shares	072	48.811.980	48.811.980
3 Treasury shares and holdings (deductible item)	073	-15.684.660	-15.684.660
4 Statutory reserves	074	0	0
5 Other reserves	075	31.713.713	31.713.713
<b>IV REVALUATION RESERVES</b>	<b>076</b>	<b>0</b>	<b>0</b>
<b>V FAIR VALUE RESERVES AND OTHER (ADP 078 to 082)</b>	<b>077</b>	<b>0</b>	<b>0</b>
1 Financial assets at fair value through other comprehensive income (i.e. available for sale)	078	0	0
2 Cash flow hedge - effective portion	079	0	0
3 Hedge of a net investment in a foreign operation - effective portion	080	0	0
4 Other fair value reserves	081	0	0
5 Exchange differences arising from the translation of foreign operations (consolidation)	082	0	0
<b>VI RETAINED PROFIT OR LOSS BROUGHT FORWARD (ADP 084-085)</b>	<b>083</b>	<b>248.915.889</b>	<b>310.461.481</b>
1 Retained profit	084	248.915.889	310.461.481
2 Loss brought forward	085	0	0
<b>VII PROFIT OR LOSS FOR THE BUSINESS YEAR (ADP 087-088)</b>	<b>086</b>	<b>99.509.266</b>	<b>92.347.615</b>
1 Profit for the business year	087	99.509.266	92.347.615
2 Loss for the business year	088	0	0
<b>VIII MINORITY (NON-CONTROLLING) INTEREST</b>	<b>089</b>	<b>0</b>	<b>0</b>
<b>B) PROVISIONS (ADP 091 to 096)</b>	<b>090</b>	<b>1.413.802</b>	<b>1.413.802</b>
1 Provisions for pensions, termination benefits and similar obligations	091	1.413.802	1.413.802
2 Provisions for tax liabilities	092	0	0
3 Provisions for ongoing legal cases	093	0	0
4 Provisions for renewal of natural resources	094	0	0
5 Provisions for warranty obligations	095	0	0
6 Other provisions	096	0	0
<b>C) LONG-TERM LIABILITIES (ADP 098 to 108)</b>	<b>097</b>	<b>119.749.741</b>	<b>101.064.576</b>
1 Liabilities to undertakings within the group	098	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	099	0	0
3 Liabilities to companies linked by virtue of participating interests	100	0	0
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	101	0	0

AP A.

5 Liabilities for loans, deposits etc.	102	243.577	243.577
6 Liabilities to banks and other financial institutions	103	38.362.090	26.540.371
7 Liabilities for advance payments	104	0	0
8 Liabilities to suppliers	105	28.193.803	22.581.946
9 Liabilities for securities	106	0	0
10 Other long-term liabilities	107	33.599.921	32.410.719
11 Deferred tax liability	108	19.350.350	19.287.963
<b>D) SHORT-TERM LIABILITIES (ADP 110 to 123)</b>	<b>109</b>	<b>1.564.659.581</b>	<b>2.162.019.501</b>
1 Liabilities to undertakings within the group	110	0	0
2 Liabilities for loans, deposits, etc. of undertakings within the group	111	0	0
3 Liabilities to companies linked by virtue of participating interests	112	75.416.715	103.229.771
4 Liabilities for loans, deposits etc. of companies linked by virtue of participating interests	113	0	0
5 Liabilities for loans, deposits etc.	114	0	0
6 Liabilities to banks and other financial institutions	115	20.451.277	411.910.901
7 Liabilities for advance payments	116	1.886.124	49.808
8 Liabilities to suppliers	117	1.407.104.916	1.593.296.901
9 Liabilities for securities	118	0	0
10 Liabilities to employees	119	15.395.639	12.195.766
11 Taxes, contributions and similar liabilities	120	33.989.743	30.048.653
12 Liabilities arising from the share in the result	121	15.405	29.567
13 Liabilities arising from fixed assets held for sale	122	0	0
14 Other short-term liabilities	123	10.399.762	11.258.134
<b>E) ACCRUALS AND DEFERRED INCOME</b>	<b>124</b>	<b>4.325.033</b>	<b>10.101.851</b>
<b>F) TOTAL – LIABILITIES (ADP 067+090+097+109+124)</b>	<b>125</b>	<b>2.329.076.190</b>	<b>2.967.911.704</b>
<b>G) OFF-BALANCE SHEET ITEMS</b>	<b>126</b>	<b>156.539.827</b>	<b>140.745.191</b>

OK π.

**STATEMENT OF PROFIT OR LOSS**  
for the period 01.01.2022 to 30.09.2022

in HRK

Submitter: Group Medika

Item	ADP code	Same period of the previous year		Current period	
		Cumulative	Quarter	Cumulative	Quarter
1	2	3	4	5	6
<b>I OPERATING INCOME (ADP 002 to 006)</b>	<b>001</b>	<b>3.027.977.746</b>	<b>1.030.589.118</b>	<b>3.462.320.662</b>	<b>1.202.668.772</b>
1 Income from sales with undertakings within the group	002	0	0	0	0
2 Income from sales (outside group)	003	3.010.020.996	1.025.510.146	3.436.850.548	1.195.373.913
3 Income from the use of own products, goods and services	004	0	0	0	0
4 Other operating income with undertakings within the group	005	23.000	1.500	6.005	2.252
5 Other operating income (outside the group)	006	17.933.750	5.077.472	25.464.109	7.292.607
<b>II OPERATING EXPENSES (ADP 08+009+013+017+018+019+022+029)</b>	<b>007</b>	<b>2.948.871.154</b>	<b>1.004.968.493</b>	<b>3.364.005.356</b>	<b>1.165.205.077</b>
1 Changes in inventories of work in progress and finished goods	008	0	0	0	0
2 Material costs (ADP 010 to 012)	009	2.815.252.146	958.220.758	3.218.166.710	1.115.132.926
a) Costs of raw materials and consumables	010	10.131.156	3.359.074	12.721.438	4.169.093
b) Costs of goods sold	011	2.786.516.813	948.755.303	3.184.447.229	1.103.208.904
c) Other external costs	012	18.604.177	6.106.381	20.998.043	7.754.929
3 Staff costs (ADP 014 to 016)	013	91.045.489	30.930.371	92.234.015	30.880.055
a) Net salaries and wages	014	57.519.734	19.594.574	58.340.450	19.526.726
b) Tax and contributions from salary costs	015	22.229.744	7.580.793	22.824.377	7.633.601
c) Contributions on salaries	016	11.296.011	3.755.004	11.069.188	3.719.728
4 Depreciation	017	21.615.566	7.352.899	22.707.816	7.574.849
5 Other costs	018	21.174.917	8.609.948	29.879.741	11.337.295
6 Value adjustments (ADP 020+021)	019	-216.964	-145.483	1.017.074	279.952
a) fixed assets other than financial assets	020	17.510	-1	0	0
b) current assets other than financial assets	021	-234.474	-145.482	1.017.074	279.952
7 Provisions (ADP 023 to 028)	022	0	0	0	0
a) Provisions for pensions, termination benefits and similar obligations	023	0	0	0	0
b) Provisions for tax liabilities	024	0	0	0	0
c) Provisions for ongoing legal cases	025	0	0	0	0
d) Provisions for renewal of natural resources	026	0	0	0	0
e) Provisions for warranty obligations	027	0	0	0	0
f) Other provisions	028	0	0	0	0
8 Other operating expenses	029	0	0	0	0
<b>III FINANCIAL INCOME (ADP 031 to 040)</b>	<b>030</b>	<b>6.340.704</b>	<b>1.563.847</b>	<b>14.349.182</b>	<b>3.976.915</b>
1 Income from investments in holdings (shares) of undertakings within the group	031	0	0	0	0
2 Income from investments in holdings (shares) of companies linked by virtue of participating interests	032	0	0	0	0
3 Income from other long-term financial investment and loans granted to undertakings within the group	033	0	0	0	0
4 Other interest income from operations with undertakings within the group	034	0	0	0	0
5 Exchange rate differences and other financial income from operations with undertakings within the group	035	0	0	0	0
6 Income from other long-term financial investments and loans	036	0	0	0	0
7 Other interest income	037	6.104.027	1.617.435	14.349.182	3.976.915
8 Exchange rate differences and other financial income	038	236.677	-53.588	0	0
9 Unrealised gains (income) from financial assets	039	0	0	0	0
10 Other financial income	040	0	0	0	0
<b>IV FINANCIAL EXPENSES (ADP 042 to 048)</b>	<b>041</b>	<b>3.821.534</b>	<b>825.410</b>	<b>2.170.000</b>	<b>827.980</b>
1 Interest expenses and similar expenses with undertakings within the group	042	0	0	0	0
2 Exchange rate differences and other expenses from operations with undertakings within the group	043	0	0	0	0
3 Interest expenses and similar expenses	044	3.821.534	825.410	2.085.882	829.909
4 Exchange rate differences and other expenses	045	0	0	84.118	-1.929
5 Unrealised losses (expenses) from financial assets	046	0	0	0	0
6 Value adjustments of financial assets (net)	047	0	0	0	0
7 Other financial expenses	048	0	0	0	0
<b>V SHARE IN PROFIT FROM UNDERTAKINGS LINKED BY VIRTUE OF PARTICIPATING INTERESTS</b>	<b>049</b>	<b>1.961.246</b>	<b>703.260</b>	<b>2.336.134</b>	<b>659.908</b>
<b>VI SHARE IN PROFIT FROM JOINT VENTURES</b>	<b>050</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>VII SHARE IN LOSS OF COMPANIES LINKED BY VIRTUE OF PARTICIPATING INTEREST</b>	<b>051</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>VIII SHARE IN LOSS OF JOINT VENTURES</b>	<b>052</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>IX TOTAL INCOME (ADP 001+030+049 +050)</b>	<b>053</b>	<b>3.036.279.696</b>	<b>1.032.856.225</b>	<b>3.479.005.978</b>	<b>1.207.305.595</b>
<b>X TOTAL EXPENDITURE (ADP 007+041+051 + 052)</b>	<b>054</b>	<b>2.952.692.688</b>	<b>1.005.793.903</b>	<b>3.366.175.356</b>	<b>1.166.033.057</b>
<b>XI PRE-TAX PROFIT OR LOSS (ADP 053-054)</b>	<b>055</b>	<b>83.587.008</b>	<b>27.062.322</b>	<b>112.830.622</b>	<b>41.272.538</b>
1 Pre-tax profit (ADP 053-054)	056	83.587.008	27.062.322	112.830.622	41.272.538

2 Pre-tax loss (ADP 054-053)	057	0	0	0	0
<b>XII INCOME TAX</b>	<b>058</b>	<b>14.205.965</b>	<b>4.727.574</b>	<b>20.483.007</b>	<b>7.402.139</b>
<b>XIII PROFIT OR LOSS FOR THE PERIOD (ADP 055-059)</b>	<b>059</b>	<b>69.381.043</b>	<b>22.334.748</b>	<b>92.347.615</b>	<b>33.870.399</b>
1 Profit for the period (ADP 055-059)	060	69.381.043	22.334.748	92.347.615	33.870.399
2 Loss for the period (ADP 059-055)	061	0	0	0	0
<b>DISCONTINUED OPERATIONS (to be filled in by undertakings subject to IFRS only with discontinued operations)</b>					
<b>XIV PRE-TAX PROFIT OR LOSS OF DISCONTINUED OPERATIONS (ADP 063-064)</b>	<b>062</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Pre-tax profit from discontinued operations	063	0	0	0	0
2 Pre-tax loss on discontinued operations	064	0	0	0	0
<b>XV INCOME TAX OF DISCONTINUED OPERATIONS</b>	<b>065</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Discontinued operations profit for the period (ADP 062-065)	066	0	0	0	0
2 Discontinued operations loss for the period (ADP 065-062)	067	0	0	0	0
<b>TOTAL OPERATIONS (to be filled in only by undertakings subject to IFRS with discontinued operations)</b>					
<b>XVI PRE-TAX PROFIT OR LOSS (ADP 055-+062)</b>	<b>068</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Pre-tax profit (ADP 068)	069	0	0	0	0
2 Pre-tax loss (ADP 068)	070	0	0	0	0
<b>XVII INCOME TAX (ADP 058+065)</b>	<b>071</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>XVIII PROFIT OR LOSS FOR THE PERIOD (ADP 068-071)</b>	<b>072</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Profit for the period (ADP 068-071)	073	0	0	0	0
2 Loss for the period (ADP 071-068)	074	0	0	0	0
<b>APPENDIX to the P&amp;L (to be filled in by undertakings that draw up consolidated annual financial statements)</b>					
<b>XIX PROFIT OR LOSS FOR THE PERIOD (ADP 076+077)</b>	<b>075</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Attributable to owners of the parent	076	0	0	0	0
2 Attributable to minority (non-controlling) interest	077	0	0	0	0
<b>STATEMENT OF OTHER COMPREHENSIVE INCOME (to be filled in by undertakings subject to IFRS)</b>					
<b>I PROFIT OR LOSS FOR THE PERIOD</b>	<b>078</b>	<b>69.381.043</b>	<b>22.334.748</b>	<b>92.347.615</b>	<b>33.870.399</b>
<b>II OTHER COMPREHENSIVE INCOME/LOSS BEFORE TAX (ADP 80+ 87)</b>	<b>079</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>III Items that will not be reclassified to profit or loss (ADP 081 to 085)</b>	<b>080</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Changes in revaluation reserves of fixed tangible and intangible assets	081	0	0	0	0
2 Gains or losses from subsequent measurement of equity instruments at fair value through other comprehensive income	082	0	0	0	0
3 Fair value changes of financial liabilities at fair value through statement of profit or loss, attributable to changes in their credit risk	083	0	0	0	0
4 Actuarial gains/losses on the defined benefit obligation	084	0	0	0	0
5 Other items that will not be reclassified	085	0	0	0	0
6 Income tax relating to items that will not be reclassified	086	0	0	0	0
<b>IV Items that may be reclassified to profit or loss (ADP 088 to 095)</b>	<b>087</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Exchange rate differences from translation of foreign operations	088	0	0	0	0
2 Gains or losses from subsequent measurement of debt securities at fair value through other comprehensive income	089	0	0	0	0
3 Profit or loss arising from effective cash flow hedging	090	0	0	0	0
4 Profit or loss arising from effective hedge of a net investment in a foreign operation	091	0	0	0	0
5 Share in other comprehensive income/loss of companies linked by virtue of participating interests	092	0	0	0	0
6 Changes in fair value of the time value of option	093	0	0	0	0
7 Changes in fair value of forward elements of forward contracts	094	0	0	0	0
8 Other items that may be reclassified to profit or loss	095	0	0	0	0
9 Income tax relating to items that may be reclassified to profit or loss	096	0	0	0	0
<b>V NET OTHER COMPREHENSIVE INCOME OR LOSS (ADP 080+087-086 - 096)</b>	<b>097</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>VI COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 078+097)</b>	<b>098</b>	<b>69.381.043</b>	<b>22.334.748</b>	<b>92.347.615</b>	<b>33.870.399</b>
<b>APPENDIX to the Statement on comprehensive income (to be filled in by undertakings that draw up consolidated statements)</b>					
<b>VI COMPREHENSIVE INCOME OR LOSS FOR THE PERIOD (ADP 100+101)</b>	<b>099</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
1 Attributable to owners of the parent	100	0	0	0	0
2 Attributable to minority (non-controlling) interest	101	0	0	0	0

AB J.

**STATEMENT OF CASH FLOWS - indirect method**  
for the period 01.01.2022 to 30.09.2022

in HRK

Submitter: Group Medika			
Item	ADP code	Same period of the previous year	Current period
1	2	3	4
<b>Cash flow from operating activities</b>			
1 Pre-tax profit	001	83.587.008	112.830.622
2 Adjustments (ADP 003 to 010):	002	18.566.270	9.676.924
a) Depreciation	003	21.615.566	22.707.816
b) Gains and losses from sale and value adjustment of fixed tangible and intangible assets	004	-975.274	-5.536.812
c) Gains and losses from sale and unrealised gains and losses and value adjustment of financial assets	005	-216.964	1.017.073
d) Interest and dividend income	006	-6.104.027	-14.349.182
e) Interest expenses	007	3.821.534	2.085.882
f) Provisions	008	0	0
g) Exchange rate differences (unrealised)	009	-1.261.686	-494.875
h) Other adjustments for non-cash transactions and unrealised gains and losses	010	1.687.121	4.247.022
<b>I Cash flow increase or decrease before changes in working capital (ADP 001+002)</b>	<b>011</b>	<b>102.153.278</b>	<b>122.507.546</b>
3 Changes in the working capital (ADP 013 to 016)	012	104.180.566	-175.672.075
a) Increase or decrease in short-term liabilities	013	-70.082.109	210.999.964
b) Increase or decrease in short-term receivables	014	199.542.873	-301.753.779
c) Increase or decrease in inventories	015	-25.280.198	-84.918.260
d) Other increase or decrease in working capital	016	0	0
<b>II Cash from operations (ADP 011+012)</b>	<b>017</b>	<b>206.333.844</b>	<b>-53.164.529</b>
4 Interest paid	018	-3.381.389	-1.754.540
5 Income tax paid	019	-7.355.110	-24.459.789
<b>A) NET CASH FLOW FROM OPERATING ACTIVITIES (ADP 017 to 019)</b>	<b>020</b>	<b>195.597.345</b>	<b>-79.378.858</b>
<b>Cash flow from investment activities</b>			
1 Cash receipts from sales of fixed tangible and intangible assets	021	2.468.863	6.815.401
2 Cash receipts from sales of financial instruments	022	1.523	0
3 Interest received	023	6.088.125	14.338.563
4 Dividends received	024	1.176.000	0
5 Cash receipts from repayment of loans and deposits	025	5.293.722	6.115.697
6 Other cash receipts from investment activities	026	7.562	4.436.685
<b>III Total cash receipts from investment activities (ADP 021 to 026)</b>	<b>027</b>	<b>15.035.795</b>	<b>31.706.346</b>
1 Cash payments for the purchase of fixed tangible and intangible assets	028	-65.307.353	-12.555.757
2 Cash payments for the acquisition of financial instruments	029	0	0
3 Cash payments for loans and deposits for the period	030	0	-600.000
4 Acquisition of a subsidiary, net of cash acquired	031	-10.182.341	-13.894.857
5 Other cash payments from investment activities	032	-6.876	-59.700
<b>IV Total cash payments from investment activities (ADP 028 to 032)</b>	<b>033</b>	<b>-75.496.570</b>	<b>-27.110.314</b>
<b>B) NET CASH FLOW FROM INVESTMENT ACTIVITIES (ADP 027 +033)</b>	<b>034</b>	<b>-60.460.775</b>	<b>4.596.032</b>
<b>Cash flow from financing activities</b>			
1 Cash receipts from the increase in initial (subscribed) capital	035	0	0
2 Cash receipts from the issue of equity financial instruments and debt financial instruments	036	0	0
3 Cash receipts from credit principals, loans and other borrowings	037	381.273.577	520.000.000
4 Other cash receipts from financing activities	038	0	0
<b>V Total cash receipts from financing activities (ADP 035 to 038)</b>	<b>039</b>	<b>381.273.577</b>	<b>520.000.000</b>
1 Cash payments for the repayment of credit principals, loans and other borrowings and debt financial instruments	040	-478.327.569	-141.891.892

AB π.

2 Cash payments for dividends	041	-38.155.600	-40.535.600
3 Cash payments for finance lease	042	-3.534.399	-3.267.765
4 Cash payments for the redemption of treasury shares and decrease in initial (subscribed) capital	043	0	0
5 Other cash payments from financing activities	044	-8.660.213	-10.188.242
<b>VI Total cash payments from financing activities (ADP 040 to 044)</b>	<b>045</b>	<b>-528.677.781</b>	<b>-195.883.499</b>
<b>C) NET CASH FLOW FROM FINANCING ACTIVITIES (ADP 039 +045)</b>	<b>046</b>	<b>-147.404.204</b>	<b>324.116.501</b>
1 Unrealised exchange rate differences in respect of cash and cash equivalents	047	0	0
<b>D) NET INCREASE OR DECREASE IN CASH FLOWS (ADP 020+034+046+047)</b>	<b>048</b>	<b>-12.267.634</b>	<b>249.333.675</b>
<b>E) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD</b>	<b>049</b>	<b>78.467.830</b>	<b>85.107.647</b>
<b>F) CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD(ADP 048+049)</b>	<b>050</b>	<b>66.200.196</b>	<b>334.441.322</b>

15 27.

STATEMENT OF CHANGES IN EQUITY  
for the period from 1.1.2022 to 30.9.2022

in HK\$

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
	Retained profits	Share premium	Capital reserves	Legal reserves	Reserves for contingencies	Reserves for employee benefits	Other reserves (attributable to equity holders)	Statutory reserves	Other reserves	Reserves for contingencies	Reserves for employee benefits	Other reserves (attributable to equity holders)	Statutory reserves	Other reserves	Retained profits	Share premium	Capital reserves	Legal reserves	Reserves for contingencies
1. Balance at the start of the reporting period	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2. Changes in accounting policies	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3. Correction of errors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4. Balance on the first day of the previous business year (restated) (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5. Profit of the period	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
6. Exchange rate differences from translation of foreign operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7. Changes in revaluation reserves of land, buildings and intangible assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8. Gains or losses from subsequent revaluation of financial assets at fair value	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9. Profit or loss arising from revaluation of equity instruments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10. Profit or loss arising from the disposal of a net investment in a foreign operation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11. Share in other comprehensive income/loss of component entities by virtue of	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12. Other changes in equity unrelated to owners	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13. Other changes in equity unrelated to owners	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
14. Tax on transactions recognized directly in equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
15. Decrease in total (attributable) capital (from the revaluation of property, plant and equipment)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16. Decrease in total (attributable) capital arising from the revaluation of property, plant and equipment	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17. Decrease in total (attributable) capital arising from the revaluation of profit	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18. Revaluation of financial assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
19. Payments from reserves to shareholders	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20. Payments of share in previous period	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
21. Transfers to reserves according to the articles of association	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22. Transfers to reserves according to the articles of association	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
23. Balance at the end of the reporting period	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24. Balance on the last day of the previous business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
25. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
26. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
27. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
28. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
29. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
30. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
31. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
32. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
33. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
34. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
35. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
36. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
37. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
38. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
39. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
40. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
41. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
42. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
43. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
44. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
45. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
46. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
47. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
48. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
49. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
50. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
51. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
52. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
53. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
54. Balance on the last day of the current business year reporting period (A/C# 01 to 04)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Handwritten initials and signature.

"FINANCIAL STATEMENT NOTES  
(are compiled for quarterly reporting periods)

Issuer: MEDIKA d.d.

OIB: 94818858923

Reporting period: [01.01.2022.](#) - [30.09.2022.](#)

Notes to the financial statements for quarterly periods include:

a) an explanation of business events that are significant for understanding the changes in the statement of financial position and business results for the reporting quarter for the issuer's quarter, ie information related to those events is published and relevant information published in the last annual financial report is updated ( paragraphs 15 to 15C of IAS 34 - Financial Reporting for Interim Years),

The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards as adopted by the European Union (IFRS). The consolidated financial statements of the Group have been prepared under the historical cost convention, unless otherwise stated.

The preparation of consolidated financial statements in conformity with International Financial Reporting Standards as adopted by the European Union (IFRS) requires the use of certain critical accounting estimates.

On 30.09.2022. year in relation to the beginning of the year Medika d.d. increased credit indebtedness by HRK 378,1 million.

On February 1, 2022, ZU Ljekarna Prima Pharma was purchased and the Ljubica Pleško Pharmacy was merged.

On September 1, 2022, ZU Ljekarna Prima Pharma was merged ZU Ljekarna Delonga.

Significant business events and transactions in the observed period, which are important for understanding the changes in the Statement of Financial Position and Business Results are explained in pdf document - Interim Management Report for H-X 2022 Group Medika, which was published simultaneously on this website Medika dd [www.medika.hr](http://www.medika.hr), on the website of the Zagreb Stock Exchange d.d. and submitted to the Official Register of Prescribed Information at the Croatian Financial Services Supervisory Agency.

b) information where access to the latest annual financial statements is provided, in order to understand the information published in the notes to the financial statements prepared for the reporting quarter,

The notes to the financial statements are included in the audited annual financial statements of the Medika Group. The audited annual financial statements for 2021 are available on the website of Medika d.d. [www.medika.hr](http://www.medika.hr), on the website of the Zagreb Stock Exchange d.d. and was submitted to the Official Register of Prescribed Information at the Croatian Financial Services Supervisory Agency.

c) a statement that the same accounting policies are applied in preparing the financial statements for the quarterly period as in the most recent annual financial statements or, if those accounting policies have changed, a description of the nature and effect of the change (paragraph 16A (a) of IAS 34 Financial Reporting for periods during the year),

The Medika Group states that the accounting policies are applied in the financial statements for the period [01.01.-30.09.2022.](#) as well as in the annual financial statements for 2021.

d) an explanation of the business results in the event that the issuer performs activities of a seasonal nature (paragraphs 37 and 38 of IAS 34 - Financial Reporting for Periods during the Year)

The Medika Group does not perform activities of a seasonal nature.





e) other disclosures required by IAS 34 - Financial Reporting for the Periods during the year  
Receivables from customers, related companies and participating companies amount to HRK 1 billion 624 million and record a increase of 22,19% compared to the beginning of the year due to improved collection.

Reclassification:

AOP 119 Liabilities to employees include short-term provisions.

Assets with the right of use are stated within long-term intangible assets by type of assets, while lease liabilities are stated within other long-term and short-term liabilities.

Interest payable on loans is stated within other short-term liabilities.

f) in addition to the above information, the following information shall be disclosed in the notes to the financial statements for the quarterly periods:

1. name, registered office of the undertaking (address), legal form of the undertaking, country of establishment, registration number of the entity, personal identification number and, if applicable, that the undertaking is in liquidation, bankruptcy, summary winding up or extraordinary administration

PARENT COMPANY INFORMATION:

Name of the issuer: Medika d.d.,

Headquarters: Capraška 1, 10000 Zagreb

Legal form: joint stock company

Country of establishment: Republic of Croatia

MBS: 080027531

OIB: 94818858923

2. adopted accounting policies (only an indication of whether there has been a change compared to the previous period)

During the reporting period, the Medika Group did not change its accounting policies compared to the previous year.

3. the total amount of any financial liabilities, guarantees or contingencies not included in the balance sheet, as well as an indication of the nature and form of any actual insurance provided; all liabilities relating to the pensions of an entrepreneur within a group or company related to a participating interest are disclosed separately

For a certain part of liabilities to suppliers, leases and loans (which are shown in the balance sheet), the Medika Group issued bank guarantees or debentures as collateral.

Liabilities from provisions for pensions are presented in the balance sheet in accordance with IAS-19.

4. the amount and nature of individual items of income or expenditure of exceptional size or occurrence

Medika Group in the reporting period 01.01.-30.09.2022. have generated consolidated sales revenues in the amount of HRK 3,436,851 thousand (in the period 01.01.-31.09.2021., HRK 3,010,021 thousand).

5. amounts owed by the entrepreneur and maturing after more than five years, as well as the total debts of the entrepreneur covered by valuable insurance provided by the entrepreneur, with an indication of the type and form of insurance

Medika Group on 30.09.2022. have liabilities that fall due after more than 5 years and are entirely related to operating lease liabilities in the amount of HRK 5,838 thousand.

Long-term tangible assets with a net book value as of September 30, 2022 are pledged as collateral for the loan amounts to HRK 124,910 thousand.

ASB A

6. average number of employees during the current period

Average number of employees of the Medika Group during the current period 01.01.-30.09.2022. amounts to 945 employees (during the period 01.01.-30.09.2021. the average number of employees was 910 employees).

7. if the entrepreneur in the business year in accordance with the regulations capitalized the cost of salaries in part or in full, information on the amount of total employee costs during the year broken down into the amount directly charged to the period and the amount capitalized in the value of assets during the period. for each part separately states the total amount of net salaries and the amount of taxes, contributions from salaries and contributions to salaries

The Medika Group did not capitalize the cost of salaries during the reporting period.

8. if provisions for deferred tax, deferred tax balances at the end of the business year and movements of these balances during the business year are recognized in the balance sheet

Deferred tax assets on 30.09.2022. amounts to HRK 1,038 thousand and records an increase of HRK 39 thousand from the beginning of the year.

Deferred tax assets (in thousands of HRK)

Situation as on 31 December 2021	999
Income tax on income statement	-
Income tax in favor of income statement	39
Stand on 30.09.2022. year	1,038

9. the name and registered office of each undertaking in which the undertaking, alone or through a person acting in his own name but on behalf of the undertaking, holds a participating share in the capital, showing the amount of capital held, the amount of total capital and reserves, business years of the undertaking concerned, for which the annual financial statements have been adopted; information on capital and reserves and profit or loss may be omitted if the undertaking in question does not publish its balance sheet and is not under the control of another undertaking

Medika d.d. has 100% stake in ZU Ljekarna Prima and the associated company ZU Ljekarna Jagatić in which it has a 49% stake.

10. number and nominal value, or if there is no nominal value, the book value of shares or stakes subscribed during the business year within the authorized capital

No new shares are subscribed during the business year.

Share capital of the Medika Group as at 30.09.2022. is HRK 209,244,420 and is divided into 30,194 shares. The nominal value of one share is HRK 6,930.

11. the existence of any certificates of participation, convertible debentures, guarantees, options or similar securities or rights, indicating their number and the rights conferring

The Medika Group has no certificates of participation, convertible debentures, guarantees, options or similar securities or rights.

12. name, registered office and legal form of each undertaking in which the undertaking has unlimited liability

Not applicable.

13. name and registered office of the undertaking compiling the quarterly consolidated financial statements of the largest group of undertakings in which the undertaking participates as a controlled member of the group

Not applicable.

14. the name and registered office of the undertaking which draws up the quarterly consolidated financial statements of the smallest group of undertakings in which the undertaking participates as a controlled member and which is also included in the group of undertakings referred to in point 13.

Not applicable.

15. the place where copies of the quarterly consolidated financial statements referred to in points 13 and 14 can be obtained, provided that they are available

Not applicable.

16. the nature and business purpose of undertakings' arrangements not included in the balance sheet and the financial impact of those arrangements on the undertaking, provided that the risks or rewards of such arrangements are material and the disclosure of such risks or rewards is necessary to assess the undertaking's financial position.

Medika Group has no material arrangements with companies that are not included in the financial statements as at 30.09.2022. years.

17. the nature and financial impact of significant events that occurred after the balance sheet date and were not reflected in the income statement or balance sheet

The Medika Group has no significant events that occurred after the balance sheet date and are not reflected in the income statement or balance sheet.

Regarding EU restriction measures, which refers to the consequences of exposure and the impact of the Russian invasion of Ukraine, Group declares that it does not have a direct business relationship with entities from Russia or Ukraine, nor is it otherwise directly exposed to those entities in its business.

Nevertheless, the Group's management estimates that an indirect impact on the Group's operations is possible due to the impact on the entire economy on global level, mainly due to the increase in the price of energy products, both raw materials, interest rates and inflation that have increased further with the Russian invasion of Ukraine. Given the uncertain extent of the impact on the economy, the Group monitors developments and assesses the impact on business, financial situation and cash flows.

“

AB 20.

Zagreb, 27 October 2022

Pursuant to the articles 462 to 471 of the Capital Market Law (Official Gazette 65/18) President of the Management Board Jasminko Herceg provides

### **STATEMENT OF LIABILITY FOR PREPARING FINANCIAL STATEMENTS OF ISSUER**

Unaudited unconsolidated and consolidated financial statements of Medika d.d. have been prepared pursuant to the International Financial Reporting Standards (IFRS) and Croatian Accounting Law.

Unaudited unconsolidated and consolidated financial statements for the period from 01 January to 30 September 2022 present true and fair view of assets and liabilities, financial position, profit or loss of the Company and the Group.

The interim management report for the unaudited financial statements for the period from 01 January to 30 September 2022 presents fair presentation of development and results of the operations and position of the Company and the Group with description of significant risks and uncertainties for the Company and the Group.

Jasminko Herceg  
*President of the Management Board*

  


**Medika** d.d.  
ZAGREB Capraška